Entity

Time filter

Source Type


Li M.,Zhengzhou University | Tang Y.,Zhengzhou University | Zang W.,Zhengzhou University | Xuan X.,Zhengzhou University | And 5 more authors.
Diagnostic Pathology | Year: 2013

Objective: To explore the expression of HAX-1 mRNA and protein in esophageal squamous cell carcinoma (ESCC) and its relation with the prognosis of patients with ESCC. Methods: The expression of HAX-1 mRNA and protein were detected with quantitative real-time RT-PCR and immunohistochemical method in 112 ESCC samples and 112 corresponding non-neoplastic samples. Survival curves were made with follow-up data. The relations of the prognosis with clinical and pathological characteristics were analyzed. Results: The expression level of HAX-1 mRNA and the strong positive rate of HAX-1 protein were significantly higher in ESCC samples (0.527 ± 0.060 and 45.54%) than that in non-neoplastic samples (0.121 ± 0.017 and 0.00%), and in ESCC samples with lymph node metastasis (0.554 ± 0.054 and 71.11%) than that in ESCC samples without lymph node metastasis (0.509 ± 0.058 and 28.36%) (all P < 0.01). HAX-1 mRNA expression level was a risk factor of lymph node metastasis in patients with ESCC (P = 0.000). There were significant differences in survival curves between lymph node metastatic group and non-metastatic group (P = 0.000), and among groups of HAX-1 protein expression +, ++and +++(P = 0.000); but no statistical significance between male patients and female patients (P = 0.119), and between ≥60 years old patients and <60 years old patients (P = 0.705). The level of HAX-1 mRNA (P = 0.000) and protein (P = 0.005) were risk factors of survival, but lymph node metastasis (P = 0.477) was not. Conclusion: There is HAX-1 over-expression in ESCC tissue and HAX-1 mRNA level is a risk factor of lymph node metastasis. The level of HAX-1 mRNA and protein were risk factors of survival in patients with ESCC. HAX-1 may be a novel therapeutic target for ESCC treatment. Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5130393079296037. © 2013 Li et al.; licensee BioMed Central Ltd.


Li M.,Zhengzhou University | Zang W.,Zhengzhou University | Wang Y.,Zhengzhou University | Ma Y.,Henan Medical College For Stuff And Workers | And 5 more authors.
Tumor Biology | Year: 2014

Linzhou City in northern China has a high incidence of esophageal squamous cell carcinoma (ESCC). This study retrospectively analyzed the data of 231 cases with ESCC collected from 1998 to 2012. Mutations of DNA polymerase β (polβ) gene in the ESCC samples from patients in Linzhou City were examined by amplifying polβ cDNA by RT-PCR followed by cloning and sequencing. Mutations in polβ were found in 105 cases (45.9 %). Nine types of mutations were identified in the polβ cDNA; the most common were 177-234 nt deletion (11.3 %), 462 nt G→T (9.1%), and 648 nt G→C (6.9 %). Mutations in polβ appeared to be associated with TNM status (P=0.048). Follow-up data was used for survival analysis. The overall 5-year survival rate of the 231 patients was 37.4 %; the rate for patients with wildtype (WT) polβ was 41.8 %. Compared with the WT polβ group, themedian survival for patients with specific mutations (177-234 nt deletion, 462 nt G→T, or 613 nt A→T) was significantly shorter (all P=0.000), and the 5-year survival rate decreased to 0 %. Patients with the 648 nt G→Cmutation had improved survival (P=0.000) with a 5-year survival rate of 100%. Our results identified nine types of mutations within polβ cDNA in ESCC patients with four mutations related to patient survival.


Li M.,Zhengzhou University | Zang W.,Zhengzhou University | Wang Y.,Zhengzhou University | Li Y.,Zhengzhou University | And 6 more authors.
Tumor Biology | Year: 2013

The present study analyzed the correlation of DNA polymerase β (DNA polβ) promoter mutations and activity in esophageal squamous cell carcinoma (ESCC). The DNA polβ promoter was amplified from 108 ESCC samples and adjacent paracancerous samples by PCR and cloned into the pGL3-enhancer luciferase vector. The recombined vectors were transfected into esophageal carcinoma cells (EC9706, Eca109, and KYSE30), and luciferase activity was detected using dual luciferase reporter gene technology. Eleven polβ promoter mutations were identified and submitted to GenBank. The mutation rate of the DNA polβ promoter was higher in ESCC tissues (36/108, 33.3 %) than in the paired paracancerous tissues (21/108, 19.4 %) (P = 0.021). The C → A mutation at locus -37 was the hotspot mutation in cancerous tissues, and its frequency was higher in ESCC tissues (26/108) than in paracancerous tissues (7/108) (P = 0.00). The highest relative luciferase activity (RLA) was observed in the DNA polβ promoter, with a C → A mutation at -37. Significant differences in RLA were observed between mutant DNA polβ promoters (except for C detected at -19, T → C at -194, C → A at -37, and T → C at 30) and the wild-type DNA polβ promoter (P = 0.000), and RLA was significantly higher in ESCC tissues than in paracancerous tissues (P = 0.003). Our findings suggest that the upregulation of transcriptional activity induced by mutations in the DNA polβ promoter in ESCC tissues may be one of the molecular mechanisms mediating abnormal overexpression of DNA polβ in ESCC. © 2013 International Society of Oncology and BioMarkers (ISOBM).


Ma Y.,Zhengzhou University | Ma Y.,Henan Medical College For Stuff And Workers | Feng L.,Zhengzhou University | Li M.,Zhengzhou University | And 7 more authors.
Life Science Journal | Year: 2010

Objective: To construct an anti-HIV/AIDS agents screening system by handling human CXCR4 promoter with medicated serum. Medthods: Human CXCR4 (CXC Chemokine Receptor 4) promoter gene was inserted into the reporter vector pGL4. Recombinant plasmid pGL4-CXCR4 was transfected into Jurkat cells (the cell line of acute T lymphocyte leukemia). The stable transfected cell were screened by G418. Thirteen kinds of traditional Chinese medicine were given to rats intragastrically and the medicated serum were collected. After the stable transfected cells were handling separately by medicated serum, CXCR4 promoter expression in the cells was detected. CXCR4 protein expression in change groups cells were tested by Western blotting analysis. Result: Cortex phellodendri chinensis and Herba houttuyniae can depress the activity of the transfected CXCR4 promoter in Jurkat cell, the luciferase activity of which is lower remarkably than of control group (p<0.05). Herba lobeliae chinensis can enhance the activity of the transfected CXCR4 promoter in Jurkat cells, the luciferase activity of which is higher remarkably than that of the control group (p<0.05). Conclusion: An anti-HIV/AIDS agents screening system based on Human CXCR4 promoter was constructed. Cortex phellodendri chinensis and Herba houttuynia were presumed to have the potential anti-AIDS effect.

Discover hidden collaborations